Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;7(2):244-8.
doi: 10.1007/s13193-016-0511-7. Epub 2016 Feb 18.

Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review

Affiliations
Review

Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review

A V Padmakumar. Indian J Surg Oncol. 2016 Jun.

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery is a targeted treatment approach in which tumors that have spread through the lining of the abdomen are removed and then heated chemotherapy is perfused throughout the abdomen, with the intent of killing any remaining cancer cells that may be present after all the visible disease has been removed surgically. The chemotherapy is administered in high dosages to the targeted area and washed out, thereby limiting the systemic toxicity. The procedure usually takes 8 to 18 h and is most commonly used to treat appendiceal, colorectal or mesothelioma tumors including those that have failed standard chemotherapy and/or prior surgeries. Patients face major and life threatening derangements of their hemodynamic, respiratory and metabolic physiologic balance during the surgery and in the immediate postoperative period. Intensive monitoring and timely detection of possible complications and appropriate remedial action is crucial for better surgical results.

Keywords: HIPEC; Intensive care.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Raue W, Tsilimparis N, Langelotz C, et al. Initial results after implementation of a multimodal treatment for peritoneal malignancies. Acta Chir Belg. 2011;111:68–72. - PubMed
    1. Königsrainer I, Beckert S, Lehmann T, et al. Peritoneal carcinomatosis. Chirurg. 2011;82:375–380. doi: 10.1007/s00104-010-2049-5. - DOI - PubMed
    1. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–685. doi: 10.1200/JCO.2008.19.7160. - DOI - PubMed
    1. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma:multiinstitutional experience. J Clin Oncol. 2009;27:6237–6242. doi: 10.1200/JCO.2009.23.9640. - DOI - PubMed
    1. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–2432. doi: 10.1245/s10434-008-9966-2. - DOI - PubMed

LinkOut - more resources